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Abstract
Background: Human papillomavirus (HPV) E6/E7 type-specific oncogenes are required for cervical carcinogenesis.
Current PCR protocols for genotyping high-risk HPV in cervical screening are not standardized and usually use
consensus primers targeting HPV capsid genes, which are often deleted in neoplasia. PCR fragments are detected
using specialized equipment and extra steps, including probe hybridization or primer extension. In published
papers, analytical sensitivity is typically compared with a different protocol on the same sample set.
A single-tube multiplex PCR containing type-specific primers was developed to target the E6/E7 genes of two low-
risk and 19 high-risk genotypes (HPV6, 11 and 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and
82) and the resulting short fragments were directly genotyped by high-resolution fluorescence capillary
electrophoresis.
Results: The method was validated using long oligonucleotide templates, plasmid clones and 207 clinical samples
of DNA from liquid-based cytology, fresh and formalin-fixed specimens and FTA Microcards
® imprinted with cut
tumor surfaces, swabbed cervical cancers or ejected aspirates from nodal metastases of head and neck carcinomas.
Between one and five long oligonucleotide targets per sample were detected without false calls. Each of the 21
genotypes was detected in the clinical sample set with up to five types simultaneously detected in individual
specimens. All 101 significant cervical neoplasias (CIN 2 and above), except one adenocarcinoma, contained E6/E7
genes. The resulting genotype distribution accorded with the national pattern with HPV16 and 18 accounting for
69% of tumors. Rare HPV types 70 and 73 were present as the sole genotype in one carcinoma each. One cervical
SCC contained DNA from HPV6 and 11 only. Six of twelve oropharyngeal cancer metastases and three neck
metastases of unknown origin bore E6/E7 DNA; all but one were HPV16. One neck aspirate contained atypical
squames with HPV26.
Analytical sensitivity in dilute plasmid mixes was variable.
Conclusions: A primer-rich PCR readily detects the E6/E7 oncogenes of 21 HPV types in cellular and fixed tissue
specimens. The method is straightforward, robust and reproducible and avoids post-PCR enzymatic and
hybridization steps while detecting HPV with high clinical sensitivity in significant HPV-related neoplasia regardless
of specimen type.
Background
Alpha-human papillomaviruses (HPV) are sexually
transmitted and may infect the anogenital and oral
mucosae. They either resolve without sequelae or cause
condyloma (HPV types 6 and 11 and their relatives) or
rarely carcinoma, particularly cervical cancer and its
precursors (cervical intraepithelial neoplasia, CIN).
HPV16 and 18 account for 70% to 80% of cervical can-
cers with the remainder due to other alpha- HPV geno-
types. HPV are labeled high-risk (HR-HPV) if found in
cancers in disproportion to their prevalence; uncertainty
exists as to whether certain genotypes (e.g., HPV26, 53,
70, 73 and 82) should be classified as high-risk.
Cervical carcinogenesis depends on the deregulation of
HPV E6/E7 in cell nuclei as dysplasia progresses.
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otyping has been agreed upon, current methods gener-
ally employ the polymerase chain reaction (PCR) with
consensus primers aimed at the L1 capsid gene [1],
despite the fact that it is the E6/E7 genes which are
most reliably conserved in cervical cancer [2]. The type-
specific E6/E7 junction is also less prone to sequence
variation than other genes, which like the capsid genes
may be lost during integration of viral DNA into the
host cell genome [2-5].
By combining labeled E6/E7 primers in a multiplex
PCR (MPCR) to yield products which are size and
color-specific for each HPV genotype on capillary elec-
trophoresis, the need for nested PCR, amplicon sequen-
cing, probe hybridization or enzymatic detection steps
[6] and specialized equipment is obviated. MPCR target-
ing these type-specific oncogenes has been reported but
the methods may use proprietary technology not widely
available and require additional post-PCR treatments,
making them less suitable for small specimen volumes
in the pathology laboratory [6,7]. Capillary electrophor-
esis, on the other hand, is well established, widely avail-
able for fragment size analysis and it yields reproducible
size peaks with a tolerance of ± 0.5 nucleotide (nt). We
describe a single-tube straightforward E6/E7 MPCR cap-
able of detecting 19 HR-HPV in a test set of highly sig-
nificant lesions (CIN 2 to carcinoma) submitted as
cytology specimens, including aspirates from metastases,
as well as fresh and formalin-fixed tumor embedded in
paraffin (FFPE).
Results
We targeted in a single microfuge tube 19 definite or
probable HR-HPV genotypes (HPV types 16, 18, 26, 31,
33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82)
[8,9] and in addition low-risk (LR) HPV6 and 11 and as
a control the human b-globin gene. Table 1 lists the
accession numbers of the HPV targets in GenBank, pri-
mer sequences, labels, true amplicon sizes and their
observed electrophoretic sizes. Template DNA came
from five sources: (i) long oligonucleotides mimicking
E6/E7 targets (except for HPV types 16, 51 and 73) for
determination of electrophoretic product size, (ii) for
analytical sensitivity a test panel of 14 plasmid-cloned
HPV genotypes [10], courtesy of the WHO HPV Refer-
ence Lab, Malmö, Sweden, (iii) for clinical sensitivity,
DNA extracted from 500 μL of pelleted cellular material
in PreservCyt solution
® used for ThinPrep cytology
(Cytyc, USA), which specimens were obtained with a
cytobrush (N = 97, including 37 consecutive normal, 13
atypical, 39 dysplasias and 9 cancers), (iv) FFPE speci-
mens (N = 44, including 11 cervical dysplasias and 33
cancers) and (v) Indicating FTA Microcards
® (What-
man, Germany) with imprinted cut tumor surface or
applied swabs/aspirates (N = 64, including 30 primary
cervical carcinomas and 3 nodal metastases, in addition
to 31 aspirates of nodal metastases from head and neck
SCC). FTA cards significantly expedite sample collec-
tion, storage and preparation and have been described
previously in lymphoma MPCR [11]. Patient specimens
were de-identified to conform to the ethical guidelines
established at our institution.
Results in clinical material are presented in Table 2.
All 19 HR-HPV were detected in at least one and most
in more than two clinical samples with as many as five
genotypes observed in a single specimen (Figure 1).
Peak amplitudes almost always exceeded 1000 fluores-
cence units. LR-HPV type 6 was present in five samples,
one of which, a cervical squamous cell carcinoma
(SCC), uniquely contained the E6/E7 genes from types 6
and 11 but not from any HR-HPV. This was the only
specimen to contain HPV11.
About one-fourth of 37 consecutive samples with nor-
mal cytology were infected with HR-HPV and three of
these (8%) had multiple genotypes. In 15 consecutive
exfoliative samples of high-grade CIN (grades 2 and 3),
o n eo rm o r eH R - H P V so c c u r r e di na l li nt h ef o l l o w i n g
order of frequency (slash indicates equal frequencies):
types 16, 18/31, 33/58/66 and 45/53/59/73/82.
HPV E6/E7 genes were detected in 75 of 76 primary
or metastatic cervical carcinomas (21 adenocarcinomas
[ADCA], 55 SCC, including the single SCC containing
LR-HPV only), as single infections in 91%. The one
negative sample was a b-globin
+ ADCA (de-identifica-
tion prevented confirmation of a true primary cervical
tumor in this case). HPV16 and 18 accounted for 69%
of the 75 HPV-associated cervical cancers, and other
genotypes were in order of frequency: 31, 45, 56/59, 33/
52, 58/66 and 35/53/70, which accords with the national
statistics [12].
Coinfection with more than one HPV type occurred
less often in carcinomas in contrast to dysplastic cytol-
ogy specimens, consistent with decreased rates of multi-
ple infections among the generally older patients with
carcinoma.
Nine of 31 nodal aspirates of SCC metastases from
head and neck tumors (Table 2 footnotes 6 and 7) con-
tained HPV. The primary site in HPV
+ tumors was oro-
pharyngeal in six instances, consistent with previous
studies [13], and the origin was unknown in three. All
nine aspirates produced prominent HPV16 peaks only,
confirming the overwhelming preponderance of this
genotype and the reported lack of HPV18 in oropharyn-
geal SCC [14]. HPV26, a suspected HR-HPV [8] pre-
viously reported in extracervical SCC [15], was
unexpectedly detected as the sole type in one nodal
aspirate containing atypical squames but without a con-
firmed cancer diagnosis. This result was reconfirmed in
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primers.
HR-HPV26, 39, 51, 68 and 82 were not present in this
series of cervical carcinomas. Types 26, 53, 70, 73 and
82 are often not included in PCR protocols, partly due
to inconclusive evidence of an overincidence in cancer.
In our series, these types occurred 14 times in toto.
Among cervical SCC, HPV types 70 and 73 each
occurred once, type 53 was found in one SCC together
with type 45, while type 26 was not detected in any cer-
vical material. The rationale for inclusion of type 70 in
the MPCR as a HR-HPV is further bolstered by its gen-
otypic and biologic relation with HR-HPV [9,16].
Among cell samples with high-grade CIN, one harbored
HPV82, 31 and 33 concomitantly and another contained
HPV53, 58 and 73.
In contrast to MPCR’s high clinical sensitivity in
lesional samples, its analytical sensitivity in dilute plas-
mid-HPV templates was variable, partly depending on
whether single or multiple targets were present. Gener-
ally, six of the eight most prevalent HPV types needed
>100 genome-equivalents/μL to elicit a definitive peak,
especially if mixed with other plasmids, while half of the
remaining genotypes were detected at a concentration
10-fold less (data not shown).
The MPCR was robust in clinical samples, producing
readily interpretable peaks and results were reproducible
on repeat runs. An occasional small spurious peak due
to saturation of the laser detector disappeared after
diluting the product.
Secondary peaks attributable to primer cross-anneal-
ing appeared occasionally, mainly in cervical cytology
specimens (presumably the result of higher virus loads
in productive infections), but did not correspond in size
and color to true peaks and had amplitudes usually
below our cutoff. In theory, mispriming of a forward
primer could result in an additional peak for a given
HPV type, while a mispriming reverse primer could pre-
sent a new peak of the same or different size and color
(all fluorophores were regularly placed on the reverse
primer) as the target peak.
Forward primers in types 39, 59, 68 and 70, which are
all 20-mers and share 3 to 7 nt in their 3’ end sequence,
might offer potential mispriming among their intended
Table 1 HPV primer and product characteristics
HPV
type
Genbank
accession
no.
E6/E7
Primers
1
Product’s
molecular
size (nt)
Product’s
electrophoretic
size (nt)
2
Forward 5’ label Reverse
39 M62849 ACA GTG TCG ACG GTG CTG GA FAM GCT TTG GTC CAC GCA TAT CTG A 94 92
70 U21941 ACA GTG CCG ACA CTG CTG GA NED GGC CGT GGT CCA TGC ATA TT 95 94
68 Y14519 ACA GTG TCG SCA CTG CTG GA HEX GGG CTT TGG TCC ATG CAT AGT 95 95
18 X05015 AGT GCC ATT CGT GCT GCA AC FAM ATG TTG CCT TAG GTC CAT GCA T 98 96
56 X74483 TGG TTG GAC CGG GTC ATG T HEX CGT CTT GCA GCG TTG GTA CTT T 103 100
45 X74479 GGA CAG TAC CGA GGG CAG TGT A NED CCG GGG TCC ATG CAT ACT TAT 107 106
33 M12732 AAT ATT TCG GGT CGT TGG GC FAM AAC GTT GGC TTG TGT CCT CTC A 109 107
35 M74117 GGT GGA CAG GTC GGT GTA TGT C HEX GTT GCC TCG GGT TCC AAA TC 120 116
66 U31794 ACC GGG TCA TGT TTG CAG TGT NED CGT TTG CGG TGC AAG TTC TAA T 122 120
6/6b AF092932
X00203
CCA AGG CRC GGT TCA TAA AGC FAM GGG TCT GGA GGT TGC AGG TCT A 123 120
6a L41216 CCA AGG CGC GGT TTA TAA AGC FAM GGG TCT GGA GGT TGC AGG TCT A 123 120
31 J04353 GTG GAC AGG ACG TTG CAT AGY A HEX GGT CAG TTG CCT CAG GTT GCA 124 121/203
3
26 X74472 GGG CAG TGG AAA GGG TTG TGT NED GGT TGC GGC ACC AGA TCT AGT A 128 126
51 M62877 AAT GCG CTA ATT GCT GGC AA HEX TGC TCG TAG CAT TGC AAG TCA A 143 142
53 X74482 ATA TGT GGA CCG GGT CGT GC FAM GGC ATT GCA GGT CAA TCT CAG T 143 143
82 AB027021 ACG GGA CAG TGT GCA AAT TGC HEX TGC TCG TAG CAT TGC AAG TCA A 150 150
52 X74481 GTT GGA CAG GGC GCT GTT C NED CCT CCT CAT CTG AGC TGT CAC C 166 167
59 X77858 ACA GTG TCG TGG GTG TCG GA FAM TGC TCG TAG CAC ACA AGG TCA A 169 169
58 D90400 AGG GCG CTG TGC AGT GTG T HEX CAT CCT CGT CTG AGC TGT CAC A 172 172
11 M14119 GGG AAA GGC ACG CTT CAT AAA NED TGT CCA CCT TGT CCA CCT CAT C 190 190
16 K02718 GTG GAC CGG TCG ATG TAT GTC T HEX TCC GGT TCT GCT TGT CCA GC 209 210
73 X94165 AAC AGT GGA CCG GAC GCT GT FAM GGC AAG GCA TAC TGT GCA CTG A 258 260
b-globin NG000007 GAA GAG CCA AGG ACA GG TAC HEX CAA CTT CAT CCA CGT TCA CC 268 268
1 Each ambiguous base code S, R and Y yields two different primer sequences. HPV types 51 and 82 share identical reverse primers.
2 Default colors: FAM, blue; NED, black; HEX, green.
3 Secondary HEX peak at 203 nt is due to cross-annealing to the HPV16 reverse primer.
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shift related to anomalous product sequence and none
was seen in electropherograms with these genotypes.
Moreover, use of the “touchdown” technique in initial
PCR cycles probably abrogated any tendency of this lim-
ited sequence similarity to competitively inhibit visuali-
zation of mixed infection. For example, two mixed
HPV68/70 infections were easily detected.
In silico analysis of individual E6/E7 target sequences
queried for significant complementarity (> 85% overall
complementarity with a requirement for complete com-
plementarity in the last three 3’ bases) with any of the
primers in the master mix yielded 29 potential mis-
primed products of varying size and color derived from
16 of the 21 genotypes when testing clinical material,
none of which were of the same size but different color
from that expected for the target. Complete comple-
mentarity was noted only for HPV31, where its forward
primer amplified type 31 E6/E7 in conjunction with the
predicted homologous type 16 reverse primer. Thus,
Table 2 HPV types in clinical samples
LR-
HPV
HR-HPV
N b-
globin
HR-HPV
(%)
>1
genotype
(%)
61 11 61 82 63 13 33 53 94 55 15 25 35 65 85 96 66 87 07 38 2
Cervical
cytology
normal 37 37 9 (24%) 3 (8%) 1 0 1 2 0 0 0 0 1 0 0 1 0 3 1 0 1 2 1 0 0
ASCUS
1 12 12 6 (50%) 3 (25%) 0 0 0 3 0 0 1 0 1 3 1 1 0 0 0 0 0 0 0 0 1
columnar atypia 1 1 1 (100%) 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
CIN 1 24 24 18 (78%) 6 (25%) 2 0 4 2 0 2 3 1 1 2 2 1 0 1 1 2 1 1 1 2 0
CIN 2 11 11 11
(100%)
4 (36%) 0 0 7 3 0 2 2 0 0 0 0 0 0 0 1 0 1 0 0 0 1
CIN 3 4 4 4 (100%) 2 (50%) 0 0 3 0 0 1 0 0 0 1 0 0 1 0 1 1 1 0 0 1 0
SCC
2 9 9 9 (100%) 3 (33%) 0 0 3 1 0 2 2 0 0 1 0 2 0 1 1 1 1 0 0 0 0
subtotal 98 98 58 21 3 0 18 12 0 7 8 1 3 7 3 5 1 5 5 4 5 3 2 3 2
FFPE
CIN NOS 11 5 11
(100%)
2 (18%) 1 0 3 2 0 1 0 0 1 0 1 1 1 0 0 0 0 0 0 1 0
SCC, cervix 23 13 23
(100%)
2 (9%) 0 0 14 2 0 2 0 0 0 1 0 0 0 2 0 1 0 0 0 0 0
ADCA, cervix 10 5 9 (90%) 1 (10%) 0 0 5 3 0 0 0 0 0 1 0 0 0 0 0 1 1 0 0 0 0
subtotal 44 23 43 5 1 0 22 7 0 3 0 0 1 2 1 1 1 2 0 2 1 0 0 1 0
FTA
SCC
3 23 23 22 (96%) 1 (4%)
4 1 1 1 4 101110201111000110
ADCA
5 11 11 11
(100%)
1 (9%) 0 0 5 4 0 2 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
SCC neck
metastasis
31
6 31 10
(100%)
7
0 0 09010000000000000000
subtotal 65 65 44 2 1 1 28 5 1 3 1 1 0 2 0 1 1 1 1 1 0 0 1 0 0
total 207 186 145 29 5 1 68 24 1 13 9 2 4 11 4 7 3 8 6 7 6 3 3 5 2
1 Atypical squamous cells of undetermined significance.
2 One bronchoalveolar lavage for a HPV59
+ SCC metastasis from cervix cancer is included.
3 Includes 5 FTA imprints from consecutively resected cervical SCC (3 primary, 2 metastatic nodes) and 18 consecutive surface tumors swabbed in vivo.
4 Both low-risk HPV types 6 and 11 E6/E7 were present in a cervical SCC from an elderly woman.
5 Includes 6 FTA imprints from consecutively excised tumors (5 primary, 1 metastatic node) and 5 consecutive ADCA swabbed in vivo.
6 Primary tumors were located in the oropharynx (11), mesopharynx (2), nasopharynx (3), tongue (1), larynx (3), oral cavity (1), paranasal sinus (1), preauricular
skin (3) and unknown sites (6).
7 HPV
+ metastases were derived from 6 primary tumors in the oropharynx (5 tonsillar and 1 base of tongue) and 4 unknown sites. HPV26 was found in atypical
squames in a neck node without a confirmed diagnosis of carcinoma but is included among SCC of unknown origin.
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ary peak (Table 2 footnote 4). Other predicted spurious
amplicons included HPV66 annealing with its legitimate
forward primer and type 56 reverse primer (91% com-
plementarity) to yield a green product 1 to 2 nt larger
than that of HPV68. Nonetheless, in no case was an
apparent type 68 peak (three instances) found together
with type 66 (six instances). HPV35, if annealed to the
52 reverse primer (91% complementarity) could yield an
amplicon similar to HPV52 but this combination of pro-
ducts was not seen either.
Discussion
We developed a primer-rich MPCR which offers single-
tube economy and straightforward simplicity in genotyp-
ing 21 potentially oncogenic HPV using type-specific
E6/E7 primers. This broad spectrum and the short
resulting amplicons necessary for formalin-degraded
tumor specimens yielded a clinical sensitivity of 100%
for high-grade CIN and 99% for cervical carcinoma,
which clearly exceeds the HR-HPV detection rate
reported for general primers when product detection is
limited to the most common genotypes [17]. The rea-
sons for failure of consensus capsid primers to amplify
their target include relatively frequent base substitutions
and deletions which may affect primer annealing or
probe hybridization [2,18-20]. Importantly, our MPCR
targets the sine qua non of cervical tumorigenesis, the
E6/E7 oncogenes [21,22]. Selection pressure appears to
be minimal in codons within the E6/E7 transition zone
and sequence variations in the HPV16 E6 gene, for
example, tend largely to involve single nucleotides
upstream of the primer regi o nw eu s e di na l l2 1g e n o -
types [21].
Cervical cancer cell nuclei contain viral DNA either
integrated in the host cell genome, as free episomes or
both. If viral episomes disappear, which occurs in 20%
to 50% or more of tumor specimens, most consistently
in HPV18-induced tumors [18], only residual integrated
HPV DNA would remain in the host cell and this would
include the obligate E6/E7 oncogenes [2,4]. A recently
reported multiplex PCR targeting the E7 oncogene
showed greater analytical sensitivity than PCR with
broad-spectrum consensus L1 primers where product
detection in both analyses used bead-based hybridization
(Luminex) [23]. In the single SCC in which our MPCR
detected both HPV6 and 11 (footnote 2, Table 2), gen-
eral L1 primers (GP5+/6+) in a PCR on the same
patient sample followed by bead-based hybridization
typing identified HPV6 but failed to identify HPV11,
whereas a singleplex PCR with our type 11 E6/E7 pri-
mers repeatedly confirmed the original result.
When compared with cytology, HPV genotyping by
PCR offers higher sensitivity but lower specificity in
detecting intraepithelial neoplasia [24] and PCR geno-
typing has been introduced as a means of triaging in
cervical cancer screening programs. Ultimately, molecu-
lar methods may replace cytologic screening, in which
case longitudinal testing using different PCR protocols
may be expected to yield conflicting results. This makes
a single, uniform, highly sensitive and reliable platform
desirable for use in all relevant specimens, regardless of
where in the diagnostic chain the specimen is obtained:
screening, tissue biopsy/resection and eventual confir-
mation of metastasis by aspiration cytology or excision
[25-28].
Our detection of rare HR-HPV in high-grade CIN and
several suspected HR-HPV types in carcinoma points
out that a relatively broad-spectrum multiplex PCR cap-
able of typing all cervical carcinomas offers a desirable
level of coverage but could still miss the rare tumor
related to a low-risk HPV not covered in the analysis. In
this regard, primers for additional genotypes could prob-
ably be added to the 46 already present in our MPCR
without adversely affecting efficiency.
Figure 1 MPCR electropherogram in multiple infection.A n
autoscaled electropherogram of a single CIN 3 sample contained
HPV E6/E7 types 16, 31, 45, 59 and 66, which are resolved in three
panels, each representing a separate color channel (a red size
marker channel is not shown). The X-axis indicates product size in
nucleotides and the Y-axis shows fluorescence intensity in arbitrary
units. The upper panel contains a single blue peak at 169 nt,
corresponding to HPV59. In the middle panel, green peaks at 121,
210 and 268 nt confirm HPV31, HPV16 and the b-globin control,
respectively. The bottom panel’s black peak at 106 nt indicates
HPV45 and the second peak at 121 nt matches HPV66. In the
routine electropherogram with composite channels, peaks for types
31 and 66 overlap but are easily identified by color.
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gives lower analytical sensitivity, which would militate
against its use in detecting infection per se or minimal
residual malignant disease (cf., lymphproliferative dis-
eases), in detection scenarios in the present study clini-
cal sensitivity is more relevant and this was retained. If
appropriately automated, scaled and tested on a larger
population sample, our MPCR might be less likely to
overburden triaging schemes with excessive detection of
infections destined to resolve [29].
The cost of materials for the MPCR (unoptimized for
use in screening) including primers and reagents, was
about USD 7 per sample as of the year 2008.
Conclusions
A primer-rich PCR readily detects the E6/E7 oncogenes
of 21 HPV types in fresh and fixed cytology and tissue
specimens. The method is straightforward, robust,
avoids post-PCR sequencing and hybridization steps by
using fragment size analysis and detects HPV with high
sensitivity in significant HPV-related neoplasia regard-
less of specimen type.
Methods
Primer and product details
Primer parameters were adjusted to yield as many
amplicons separated in size by ~3 or more nucleotides
as possible while maintaining high PCR efficiency. Pri-
mer pairs were chosen to avoid potential duplex for-
mation within and between pairs. Each primer pair
with amplicon was used in a BLAST query of human
and viral databases http://www.ncbi.nlm.nih.gov/tools/
primer-blast/ to confirm the sequence’s uniqueness for
each HPV genotype and to adjust primers for minor
polymorphisms in primer binding sites reported for
subtype variants. All reverse primers were synthesized
with 5’ labels (FAM, blue; HEX, green or NED, black),
which were alternated with each increase in corre-
sponding amplicon size. Primers for the human b-glo-
bin control gene were designed to yield a green 268 nt
product. The result was 46 unique primers designed to
yield short products suitable for both high-molecular
weight DNA and formalin-fixed material; expected
H P Vp r o d u c ts i z e sr a n g e df r o m9 4t o2 5 8n tw i t ha l l
but two being≤190 nt. Primer sets were then synthe-
sized and purified by HPLC (Eurofins MWG/Operon,
Germany).
PCR protocol
DNA was extracted from sections and from cytology
fluid using a kit (GentraSystems, USA) according to the
manufacturer’s instructions. DNA was precipitated in
isopropanol, the pellet resuspended in 10 mM Tris-buf-
fer, pH 8.5 and 50-100 ng was used as template.
After extensive testing in >400 PCR using single and
combined primer pairs, an optimal MPCR, capable of
detecting at least 5 genotypes simultaneously in a single
tube, was determined. It used 25 μL of (obligatory) Mul-
tiplex PCR Kit
® (cat. no. 206143, Qiagen, Germany) in a
50 μL reaction, which included 5 μLo fas o l u t i o nc o n -
taining 0.3 μM of each forward and reverse primer for
b-globin and HPV types 16, 39, 66 and 68 with 0.2 μM
for all other primers. After 15 min at 95°C, 8 “touch-
down” cycles (1°C decline in annealing temperature for
each succeeding cycle) were run starting with annealing
at 65°C for 90 s in the first cycle, then 95°C, 30 s; 65°C
-1°C, 90 s for seven cycles; 72°C, 45 s, and 22 cycles
with constant parameters (95°C, 30 s; 57.5°C, 90 s; 72°C,
45 s) with a final extension at 68°C for 15 min. All E6/
E7 oligonucleotide targets were detected singly and in
mixed combinations of 4 or 5 genotypes at estimated
concentrations of 1.5 × 10
3 to 1.5 × 10
5 virus equiva-
lents per genotype per μL.
Capillary electrophoresis
One μl of PCR product was added to a mixture of 12 μl
formamide and 0.5 μlR O X5 0 0s i z es t a n d a r dp r i o rt o
heat-denaturation and loading on an ABI Prism
® 3130
Genetics Analyzer whose capillaries were filled with
POP7 polymer (minimum runtime 18 min). Data files
were analyzed in GeneMarker
®, vers. 1.75. Peaks were
called if they were ~1 nt or less in width, corresponded
to the predetermined size (± 0.5 nt) and color of a given
genotype and were ≥500 fluorescence units to allow
ready distinction from baseline.
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